Prevention of Hepatitis B Virus Transmission in Pregnancy by Praptiwi, D. R. (Dwi) & Sanityoso, A. (Andri)
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy170
REVIEW ARTICLE
????????????????????????????????
?????????????????????????
Dwi Rahayu NL Praptiwi*, Andri Sanityoso**
* Department of Internal Medicine, Faculty of Medicine, University of Indonesia/ 
Dr. Cipto Mangunkusumo General National Hospital, Jakarta 
** Division of Hepatology, Department of Internal Medicine, Faculty of Medicine, 
University of Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
ABSTRACT
Chronic hepatitis B virus infection is a serious health problem in many countries, particularly in developing 
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
hepatitis B virus (HBV) infection. Almost 50% cases of hepatitis B virus infection happen during perinatal and 
neonatal period, including vertical transmission from mother to child during pregnancy.
World Health Organization (WHO), World Gastroenterology Organization (WGO) and many countries have 
recommended immunoprophylaxis by the administration of hepatitis B vaccine and hepatitis B immunoglobulin 
(HBIg) to prevent transmission from mother to child. However, there are approximately 10-15% babies born 
from mother with hepatitis B infected by HBV through intrauterine transmission. Incidence of intrauterine 
transmission is accounted for around 43-50% if DNA of HBV in the mother is more than 107 copies/mL, although 
passive and active immunization to the baby has been administered. Therefore, administering antiviral drugs in 
pregnant women with chronic hepatitis B accompanied by immunoprophylaxis is effective in preventing hepatitis 
B infection transmission during pregnancy, particularly in decreasing the number of virus and administering 
active or even passive immunization to neonates.
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ABSTRAK
Infeksi virus hepatitis B kronik merupakan permasalah kesehatan yang serius di berbagai negara, terutama 
?????????????????????????????????????????????????????????????????????????????????????????????????????????
endemisitas infeksi virus hepatitis B (VHB). Hampir 50% kasus infeksi virus hepatitis B terjadi saat perinatal 
dan neonatal, termasuk transmisi vertikal dari ibu ke anak saat kehamilan.
World Health Organization (WHO), World Gastroenterology Organization (WGO) dan berbagai negara 
???????????????????????????????????????????????????????????????????????????????????????????????????????
untuk mencegah penularan dari ibu ke anak. Namun, masih terdapat sekitar 10-15% bayi lahir dari ibu dengan 
hepatitis B terinfeksi VHB karena penularan intrauterin. Insidens penularan intrauterin sekitar 43-50% bila 
DNA VHB ibu lebih dari 107 kopi/mL, meskipun dengan imunisasi pasif dan aktif pada bayi. Oleh karena itu, 
????????????????????????????????????????????????????????????????????????????????????????????????????????????
mencegah penularan infeksi hepatitis B saat kehamilan, yaitu dengan menurunkan jumlah virus dan memberikan 
imunisasi aktif maupun pasif pada neonatus. 
Kata kunci: hepatitis B, kehamilan, pencegahan, transmisi
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INTRODUCTION
Chronic hepatitis B virus infection is a serious 
health problem in many countries, particularly in 
developing countries.1 There are approximately 350 
million people in the whole world who suffer from 
chronic hepatitis B infection. Mortality rate for this 
disease is around 500.000 to 1.2 million people per year 
due to hepatitis B infection.2, 3,4???? ???????????????????
vertical transmission from mother to child is the main 
endemicity factor of hepatitis B virus (HBV) infection. 
Almost 50% hepatitis B virus infection cases occur 
in perinatal and neonatal period, including vertical 
transmission from mother to child during pregnancy 
In endemic countries, women in the reproductive age 
has high positive hepatitis B e antigen (HBeAg) and 
increases the transmission risk from mother to child, 
the younger age they were infected, the higher the 
possibility to become chronic hepatitis B.1,4,5 
World Health Organization (WHO), World 
Gastroenterology Organization (WGO) and various 
countries have recommended immunoprophylaxis 
by administering hepatitis B vaccine and hepatitis B 
immunoglobulin (HBIg) to prevent transmission from 
mother to child. In China, almost 85-90% transmission 
can be prevented by the administration of both 
immunoprophylaxis. It has been proved that passive 
and active immunizations may prevent perinatal 
and breastfeeding transmission effectively. This 
also supports the possibility of highest transmission 
rate during perinatal period. However, there are 
approximately 10-15% babies born from mother 
with hepatitis B who are infected with HBV due to 
intrauterine transmission. Risk of this failure consists 
of presence of HBeAg and increased titre HBsAg 
and number of HBV DNA in mothers.1 Incidence of 
intrauterine transmission is approximately 43-50% if 
HBV DNA in the mother is more than 107 copies/mL, 
although passive and active immunizations have been 
administered to the baby. Therefore, administration 
of antiviral drugs in pregnant women with chronic 
hepatitis B along with the immunoprophylaxis is 
considered effective in decreasing transmission of 
hepatitis B infection during pregnancy, which is by 
decreasing viral load and administering active or even 
passive immunizations in neonates.1,3,4 
Evaluation and management of pregnant women 
with chronic hepatitis B is a challenging issue and 
requires good understanding towards the progress 
of chronic hepatitis B in pregnancy, particularly if 
considering antiviral therapy administration.3,4 Thus, 
holistic management in pregnant women with chronic 
hepatitis B is indispensable, with various preventive 
modalities. This is with one purpose to decrease the 
transmission rate of hepatitis B virus infection from 
mother to child that eventually decreases the endemicity 
of chronic hepatitis B. In this review, we will discuss 
??????????????????? ??????????????????????????????? ????
pregnancy, active and passive immunoprophylaxis in 
neonates, antiviral administration in pregnant women, 
labour, and lactation.
??????????????????????????????? ?????-
?????????????????
Several physiological changes occur during 
pregnancy, including the increase of metabolism 
and nutrition consumption. These changes happen to 
support the needs of pregnant women along with the 
fetal development. Abundant productions of hormones 
in pregnant women also need to be metabolized 
???? ?????????? ??? ???? ??????? ????? ?????????????? ????
metabolism of fetus depend on the mother’s liver 
function. This is related to the previous exacerbation 
of liver disease and liver injury. There is a tendency 
for alanine aminotransferase (ALT) to increase in the 
last trimester and after delivery.4
Hepatitis B virus infection will not increase 
mortality and teratogenic effect in pregnancy. 
However, there was increase of incidence of babies 
to be born premature and low birth weight (LBW) in 
acute infection compared to the general population. 
Although gestational diabetes mellitus, antepartum 
bleeding, premature baby and lower Apgar score 
more often happen in chronic hepatitis B.2,4 This 
acute hepatitis B infection need to be differentiated 
from other acute liver disease in pregnancy, such as 
intrahepatic cholestasis.2
Patients with advanced cirrhosis are usually 
amenorrhea and infertile due to hypothalamus – pituitary 
axis dysfunction, but pregnancy may successfully 
occur in well-compensated cirrhosis. In this case, 
approximately 50% experienced miscarriages. The 
main risks for mother are oesophageal varies rupture 
and bleeding that occurs in 20-25%, particularly in the 
second trimester and during labour. If the presence of 
oesophageal varices is known before pregnancy, women 
who are planning to be pregnant have to be treated 
??????????????? ??? ?????? ???? ??????????????? ?????????
then in the second trimester they are recommended to 
undergo endoscopy. If oesophageal varices are found, 
beta-blocker needs to be administered although there 
is a possible effect to the fetus.2
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Management of acute varices bleeding in pregnancy 
include the prompt endoscopy, while administration 
of vasopressin is contraindicated. Ascites and hepatic 
encephalopathy need to be treated as usual with 
diuretic, lactulose, rifaximin, and others. Patients 
who are known to have big varices, normal delivery is 
recommended to prevent abdominal surgery.2
??? ??????????? ??????????? ?????????????????????
of maternal immune system that cause the decrease 
of immune response to combat hepatitis B virus. 
??????????????????????????????????????????????????????
rejection, which is allogeneic to maternal immune 
????????????????????????? ??????? ???? ????????? ??????
of HBV DNA and decreased level of transaminase 
enzymes. After delivery there will be increased of 
maternal immunity, therefore there will be increase 
of transaminase enzymes and decrease level of HBV 
DNA.2 
Although hepatitis B infection during pregnancy 
can be well tolerated, but severe hepatitis and failure 
??? ?????? ????????? ???????? ??? ???????????? ?????????
during perinatal may happen. Therefore, the prognosis 
can be not good.4
???????????? ????? ????????????? ???
VACCINE
???????????????????????????????????????????????????
the presence of HBsAg 6 months after birth. Anti-HBe 
and anti-hepatitis B core antigen (anti-HBc) can pass 
the placenta and usually disappear at the age of 12 and 
24 months. The presence of these antibodies is not the 
marker of infection in babies.2
Screening programme in pregnant women with the 
purpose of identifying the presence of positive HBsAg 
in pregnant women is a standard programme. In most 
countries, this programme is routinely performed in 
pregnant women in the initial prenatal examination. 
?????????????????????????????????????????????????????
receive active and passive immunoprophylaxis at birth 
to decrease the vertical transmission of hepatitis B. 
Passive immunization is by administering HBIg, while 
passive immunization is by administering hepatitis 
B vaccine.2,4 ??????????? ???????? ??? ????? ??????????
if explanation are given to the pregnant women and 
their family, which include the hepatitis B, ways of 
transmission (such as through sexual contact, body 
??????????????????????????????????????????????????????
vaccination are the keys to success of preventing and 
controlling HBV infection. Women with hepatitis B 
should actively plan their pregnancy and evaluate the 
severity of their disease.4 
This active and passive prophylaxis administration 
is effective in preventing transmission, however 
approximately 10-15% babies are still infected by 
hepatitis B, particularly those who are born from 
mother with positive HBeAg.2,6 HBeAg in mothers may 
pass through the placenta and induce T cell tolerance 
in the womb.2 Transmission of hepatitis B infection 
may happen in prenatal period, during labour, and 
early postpartum period. Pregnant women who have 
??????????????????????????????????????????????????????
to be referred to hospitals, which have experience in 
managing hepatitis B.4 
Intrauterine hepatitis B infection, which mechanism 
is still unclear, is the main reason of immunology 
blockade failure. The high level of HBV DNA in 
the serum in pregnant women is main risk factor for 
intrauterine HBV infection to occur. This is strongly 
associated with the level of HBV DNA and HBeAg 
titre in placenta blood. This also showed that HBV may 
infect all types of placental cells (placenta decidua, 
trophoblast which consists of syncytiotrophoblast 
and cytotrophoblast, mesenchymal villi, capillary 
endothelial cells villi). Hepatitis B virus may be 
????????????????????????????????????????????????????
blood in the umbilical cord, with the presence of HBV 
DNA in these tissues.2, 7 However, it is still unclear 
if hepatitis B virus can pass through the placenta by 
?????????? ???????????? ?????? ??? ???? ????? ?????????? ???
pregnancy. This virus may pass through trophoblast 
cells using endosomal transportation system that is 
still infectious.7
HBV DNA is presence in all generation of 
spermatogenic cell and sperms of males who are 
?????????????????????? ??????????????????????????? ????
ovaries (cellular transfer). The presence of virus in 
the spermatogenic cell has a role in the transmission 
of HBV infection to neonates, where there has been 
homolog sequence of virus between father and child, in 
discordant partners. The absence of HBeAg in pregnant 
women is associated with the low viral replication and 
decreases the risk of intrauterine transmission.2
The table below showed the passive or active HBV 
immunization in term neonates. If mother is HBeAg 
positive, it is recommended to administer active or even 
??????????????????????????????????????????8
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?????????? ?????????? ???????? ????
All treatment decision for hepatitis B infection 
??????????????????????????????????????????????????????
for mother and fetus. The main problem associated with 
mother is the effect of treatment to liver disease, either 
short term or even long term. While the consideration 
for fetus is the risk of teratogenic effect in early 
embryogenesis due to drugs.2
In general, basically it is not recommended to 
initiate antiviral therapy of nucleoside analogue in 
immunotolerant hepatitis B. Because the risk of 
intrauterine infection is obviously associated with 
viremia in the mother, and most of the organs in fetus 
have developed in the third trimester, thus the strategy 
of antiviral administration is performed in the last 
trimester.1
Antiviral drug administration along with 
immunoprophylaxis in pregnant women with chronic 
hepatitis B is thought to be effective in preventing 
transmission of hepatitis B infection during pregnancy, 
which is by decreasing the viral load and administering 
passive immunization in newborn babies.10
Until now, there has still been a controversy 
regarding the group, which receive the highest 
??????? ??????????????? ???????? ??????????????????????
pregnancy. However, the available guidelines mention 
that the limit of HBV DNA > 2 x 106 IU/mL as an 
indication of antiviral therapy administration.11
Seven drugs which have been approved by Food 
and Drug Administration (FDA) for hepatitis B therapy 
are polyethylene glycol (PEG), interferon alpha 2a, 
interferon alpha 2b, lamivudine, adenoviral, entecavir, 
telbivudin and tenofovir.2,10
Table 1. Categories of antiviral drugs for hepatitis B in 
pregnancy2
Antiviral Kategori
Lamivudin C
Entecavir C
Telbivudin B
Adefovir C
Tenofovir B
Interferon alpha 2b C
Pegylated-interferon alpha 2a C
Interferon and peg-interferon are contraindicated 
during pregnancy due to its proliferative effect.1 These 
drugs can be given to reproductive age women with 
the duration of therapy for approximately 48-96 weeks, 
but it is recommended to use contraception during 
therapy.2 Patients during peg-interferon therapy, who 
are then pregnant, have to change their therapy with 
more safe drugs. Pregnant women whose therapy is 
???????????????????????????????????????????????????????
recommended to undergo strict monitoring. Similarly, 
all reproductive age women with HBV infection are 
recommended to use contraception during therapy and 
these patients have to informed adverse effects of the 
therapy during pregnancy.12
Oral antiviral drug, nucleoside analogue may 
inhibit virus proliferation, has been used in long time 
??? ???????????? ????????????????? ?????? ????? ?????????
the replication of mitochondrial DNA, thus cause the 
toxicity potency in mitochondria. Based on the safety 
category for pregnancy, 5 nucleoside analogue drugs 
?????????????????????????????????????????????????????
into C category include lamivudine, adefovir, and 
entecavir. These drugs have teratogenic or embryocidal 
effect in animals, but there are no studies in human.2
????????????????????????????????????????????????????
??????????? ?????????????????????????? ???????????????????
drug that was approved for treatment of hepatitis 
B, and most clinical experiences indicated the least 
teratogenic effect in human.2 Lamivudine for several 
years have been believed to prevent transmission of 
intrauterine hepatitis B infection during pregnancy in 
the last trimester. The preventive effect has also been 
proven. Although FDA categorized it as a C category 
drug, in 2009 European Association for the Study of the 
??????????????????????????????????????????????????1,13 
Although decrease in the number of HBV DNA until 
undetected status has been reported, lamivudine 
therapy in the last trimester did not give any guarantee 
of prevention of transmission of hepatitis B infection 
from mother to child.1
In the study performed by Xu et al using randomized 
controlled trial (RCT) method, 150 pregnant women 
with positive HbsAg and high viremia, lamivudine 
Table 1. Hepatitis B immunization in neonates8,9
Mother HBsAg Immunization Dose Schedule (months) Comments
(+) Active EngerixB 10μg/0.5 mL
HBVax-II: 5μg/0.5 mL
0, 1, 6 ????????????????????
Passive HBIg 0.5 mL ????????????????????
(-)/ ? Active EngerixB 10μg/0.5 mL
HBVax-II: 5μg/0.5 mL
0, 1, 6 Soon after birth
HBVax = Hepatitis B virus vaccine; HBIg = Hepatitis B immunoglobin 
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150 mg was given in 32 weeks pregnancy up to 4 
weeks before delivery, where both groups of neonates 
received HBIg and vaccine at birth. At the age of 1 year 
old, there were 18% infected babies born from mother 
receiving lamivudine therapy, while in the control 
?????????????????????????????????????????????????14 
Another meta-analysis study was performed in 10 RCT 
with the total of 921 pregnant women who received 
lamivudine therapy, results confirmed the safety 
?????????????????????????????????????????????????????
However, the disadvantages of this meta-analysis were 
the presence of heterogeneity of cut off in the number 
of HBV DNA that received therapy.1 
Included in the B category are telbivudin and 
tenofovir. Based on the animal study, there was no 
teratogenic or embryogenic toxicity risk, but there 
was no study in human.2 Toxicology study also 
demonstrated that telbivudin did not have toxicity in 
???????????????????????????????????????? ?????????????
toxicity in vitro.1,15 Tenofovir has high antiviral potency 
and genetic defence toward resistance, while telbivudin 
has high antiviral potency but resistance may happen 
easily.2
There are several therapy reports with telbivudin 
showing fast decrease of serum HBV DNA level. 
Several reports also showed telbivudin has better 
?????????????????????????? ??? ??????????? ???????????
hepatitis B with positive or negative HbeAg.1,15 In a 
meta-analysis study conducted by Deng Ming et al, 
there was 306 pregnant women receiving telbivudin 
600 mg therapy in the second or even third trimester 
up to 1 month after delivery. While in the control 
group, there were 270 pregnant women who did not 
receive antiviral drugs. All babies were given HBIg and 
hepatitis B vaccine at birth. It was concluded that the 
HbsAg seropositive result or the number of HBV DNA 
?????????????????????????????????????????????????????
followed-up at birth and at the age of 6-12 months.1
??????????? ???????????? ???????? ??? ????????????
HBV DNA in the third trimester or pregnancy. In a 
non-randomized study by Han et al in 190 pregnant 
women with positive HbsAg and positive HBeAg 
with virus >106 ?????????????????????????????????????
telbivudin was evaluated and compared to placebo. 
In both groups, newborn babies received passive 
or even active immunization within the first 24 
hours. Telbivudin administered during 20-32 weeks 
pregnancy up to 4 weeks after delivery if the disease 
was not active, but if the disease was chronic active, 
treatment was continued up to 28 weeks. There was 
decrease in the seropositivity of HBsAg as much as 
6.3% in telbivudin group and 30.4% in placebo group. 
????????????? ??????????????????????????? ??????????????
decrease of HBsAg or even HBV DNA as much as 
2% in telbivudin group and 13% in control group. 
Elevation of ALT postpartum occurred in 7.5% patients 
receiving telbivudin and 18.5% in placebo group. There 
was no severe hepatitis happening after the cessation 
of telbivudin in the fourth week postpartum.16
?????? ???? ???????? ????? ?????????? ???? ???????? ???
tenofovir in pregnant women. Several information 
regarding the toxicity of tenofovir were obtained 
from animal study, such as gravid rhesus monkeys, 
in which there was decreased of insulin like growth 
factor in neonates and inhibited growth in mother with 
2 months therapy.2 
In pregnant women with positive HBsAg, then 
early pregnancy evaluations are recommended. This 
includes the evaluation of HBsAg, HBeAg, anti-HBe, 
???? ?????????????????????????????????????????? ???????
or liver cirrhosis.2,4,17 In patients with high level of 
HBV DNA and active hepatitis (ALT <2 times upper 
normal limit, HBV DNA VHB >105 copies/mL) in 
the early or even in the presence of liver cirrhosis, but 
antiviral need to be given at the start of pregnancy. 
For patients with normal liver function, ALT and HBV 
DNA need to be re-evaluated in mid-pregnancy (26-28 
weeks). Patients with HBV DNA >107 copies/ mL or 
before delivering baby with positive hepatitis B and 
HBV DNA >106 copies/mL, then antiviral therapy 
(lamivudine, tenofovir or telbivudin) should be given 
in 28-30 weeks up to 4 weeks after delivery. Further, it 
has to be determined if the aforementioned therapy will 
be continued or not based on the patient’s condition. 
ALT and HBV DNA level need to be monitored in 
all pregnant women with positive HBsAg in the 1,3, 
and 6 months after delivery. Presence of hepatitis 
?????? ?????????????????????????????????????????????
anti-Hbe have to be detected. Active and passive 
immunization need to be given to all newborn babies 
as scheduled, HBV-M (HBsAg, HBeAg, anti-HBe) and 
HBV DNA level also need to be detected at birth and 
??????? ?????????????????? ?????????????????????? ????
liver cirrhosis before pregnancy, antiviral therapy need 
???????????????????????????????????????????????????????
continued during pregnancy with close monitoring.2, 4 
LABOR AND LACTATION
In the survey performed by Guo et al, from 158 
pregnant women with positive HBsAg approximately 
82% underwent caesarean delivery to prevent direct 
contact with blood or other body fluid. This is 
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performed to decrease HBV transmission from mother 
to child. Several studies stated that caesarean delivery 
could decrease HBV transmission from mother to 
child. However, several other studies found that there 
???? ??? ??????????? ??????????? ??????? ?????????????
between caesarean delivery and vaginal delivery.19
Meta-analysis from 4 randomized studies, which 
?????????????????????? ????????????????????????????
and safety of caesarean delivery (caesarean delivery 
before labour or before placental membrane rupture) 
compared with vaginal delivery in preventing hepatitis 
B transmission from mother to child. It was obtained 
that caesarean delivery has high transmission rate, 
approximately 10.5% and vaginal delivery 28% (p 
??????????????????????????????????????????????????
morbidity or child based on way of delivery. However, 
conclusion of the meta-analysis needs to be interpreted 
with caution considering the high risk of bias in all 
studies including in the analysis. Therefore, the role 
of caesarean delivery in preventing transmission of 
hepatitis B virus infection from mother to child is 
uncertain.2 Currently, there is no data, which convince 
that caesarean delivery, decrease the transmission of 
HBV infection from mother to child compared to 
vaginal delivery.2,18
Based on this information, it is important for doctors 
to decide whether or not to perform caesarean delivery, 
considering that caesarean delivery also increase 
maintenance cost, lengthening hospital stay, and may 
cause surgical complications.19
Before the availability of neonatal immunization, 
study reported hepatitis B infection in newborn babies 
from positive HbsAg mother as much as 53% who 
were given breast milk and 60% were given formula 
milk. By immunoprophylaxis administration, babies 
who were given breast milk have transmission risk 
of 0% and formula milk 3%. Latest guidelines stated 
that breast milk administration is not contraindicated 
in mother with hepatitis B virus infection who is not 
receiving antiviral therapy and their babies receiving 
immunoprophylaxis. In mother who are consuming 
therapy with lamivudine or tenofovir, breast milk 
administration is not recommended, due to the less 
data available regarding antiviral safety in lactating 
patients, although tenofovir can be detected in breast 
milk in low concentration.2, 4,12
CONCLUSION
In preventing transmission of hepatitis B infection 
in pregnancy, examination of HbsAg is recommended 
in all pregnant women, without considering previous 
results of examination or vaccination history. Pregnant 
women with high hepatitis B virus level has high risk 
of transmitting infection to the baby, although active 
or even passive prophylaxis have been given, therefore 
in this condition administration of antiviral therapy 
during the third trimester need to be considered. 
Breastfeeding is not contraindicated in women with 
hepatitis B infection, except in the administration 
of antiviral therapy, there is no clear evidence that 
caesarean delivery decreases transmission risk from 
mother to child compared to normal delivery.
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